Context Therapeutics Investor Presentation Deck
.
Rationale for Clinical Trial Collaboration
Clinical Trial Collaboration and Supply Agreement
Phase 1b/2 study of ELacestrant in combination with ONApristone in patients with advanced or metastatic ER+, PR+,HER2- breast
cancer (ELONA trial)
●
Context will sponsor the clinical trial and Menarini will supply elacestrant at no cost
Context and Menarini will form a Joint Development Committee to review the clinical trial results
MENARINI
M
Elacestrant is the first oral SERD to
show positive Ph 3 top line results¹
group
Priority Review and assigned a PDUFA
date of February 17, 2023
11 Context Therapeutics Inc. - Sept. 2022
Elacestrant +
ONA-XR
Potential to enhance elacestrant clinical
activity in metastatic breast cancer
Establish clinical proof of concept for
ONA-XR combination therapy with oral
SERD class
•
Menarini Clinical Trial Collaboration
•
context
therapeutics
ONA-XR is the most complete PR
antagonist in clinical development²
ONA-XR tolerability profile makes it a
potentially ideal combination agent³
Desire to clinically validate combination of
ONA-XR with new oral SERDS
(1) "Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021." Menarini Group, 8 Dec. 2021. Press release
(2) Afhuppe, J. Steroid Biochem. Mol. Biol. 2009, 105; Afhuppe, J. Steroid Biochem. Mol. Biol. 2010, 45
(3) Lewis, J. Drug Safety 2020View entire presentation